ALXO Stock — ALX Oncology Holdings Inc.: Cash, EV, Pipeline

Share price

$1.70

Market cap

$235.1M

Cash

$138.2M

Enterprise value

$106.6M

Balance sheet

Cash	$138.2M
Debt	$9.7M
Net cash	$128.5M
Enterprise value	$106.6M
Basic shares	138.2M shares
Fully diluted shares	157.2M shares
Fully diluted market cap	$267.2M
Cash per share	$1.00

Cash figures as of 2026-06-30. Database snapshot: 2026-09-21.

Price history

Loading ALXO daily closes…

Loading price history…

Pipeline assets

Evorpacept

Phase 2 · Active

Target CD47

Partnerships Jazz Pharmaceuticals (sponsor of Phase 1b/2 zanidatamab + evorpacept trial); Sanofi (sponsor of Phase 1/2 isatuximab + evorpacept trial in multiple myeloma); MD Anderson (investigator-sponsored Phase 1/2 trial in B-cell NHL)

Indications

HER2-positive metastatic breast cancer (with trastuzumab + chemotherapy) (Phase 2)
HER2-positive gastric/gastroesophageal junction (GEJ) cancer (ASPEN-06) (Phase 2)
B-cell non-Hodgkin lymphoma (with rituximab) (Phase 2)
Relapsed/refractory multiple myeloma (with isatuximab) (Phase 2)
Second-line metastatic colorectal cancer (ASPEN-CRC) (Phase 1)

Status note Lead program. ASPEN-06 (randomized Phase 2/3 in 2L/3L HER2+ gastric/GEJ) reported Phase 2 topline July 2024; FDA advised April 2025 that a Phase 3 vs ENHERTU would be required for a US registrational path, which the company will not pursue - gastric program available for partnerships. ASPEN-09-Breast amended August 2025 to single-arm design evaluated by CD47 expression. ASPEN-CRC paused August 2025 to focus resources on ASPEN-09-Breast. Fast Track (January 2020) and Orphan Drug (January 2022) designations for HER2 gastric/GEJ combination. CD47 overexpression identified as predictive biomarker (SITC November 2025).

ALX2004

Phase 1 · Active Modality: antibody-drug conjugate

Target EGFR

Indications

Advanced or metastatic EGFR-expressing solid tumors (Phase 1)

Status note EGFR-targeted ADC (matuzumab-derived antibody, topoisomerase I inhibitor payload); IND cleared April 2025, first patient dosed August 2025.

Per-asset detail extracted from the 10-Q filed 2026-08-06. Fields the filing does not state are marked "not disclosed" rather than filled from other sources.

No lead program on file for this company.

No active ClinicalTrials.gov trials matched to this company as sponsor or collaborator.

Institutional holders

Fund	Shares	Q/Q change	% of portfolio	Filing
OrbiMed Advisors	2,866,256	no change	0.11%	2026-08-14
ADAR1 Capital Management	533,660	+533,660	0.05%	2026-08-14

Institutional holder positions from 13F filings. Q/Q change is vs the prior quarter's filing; % of portfolio is the fund's own reported portfolio weight.

ALXO — ALX Oncology Holdings Inc.

Balance sheet

Price history

Pipeline assets

Institutional holders